Cytotoxicity Profiling and IC₅₀ Determination of Madecassoside-Loaded Ultra-Small Unilamellar Nanocarrier System on Keloid-derived fibroblast cell lines: an MTT Assay and Cell Viability AnalysisViability Analysis.
Abstract
Objective: To evaluate the in vitro cytotoxicity of a madecassoside-loaded ultra-small unilamellar nanocarrier system (MU) against keloid-derived fibroblasts and to compare it with that of the empty carrier and pure madecassoside. Design: In vitro experimental study using keloid-derived fibroblasts and the MTT colorimetric assay; each treatment was performed in triplicate. Intervention: MU, prepared from virgin coconut oil (VCO), soy lecithin and Tween 80 by sonication-aided emulsification, its empty carrier and pure madecassoside were applied to the cells at 10, 20, 30 and 40 µg/mL for 72 h. Main outcome measures: Cell viability (percentage of untreated control), the half-maximal inhibitory concentration (IC50) calculated by semilogarithmic linear regression, and cell morphology under an inverted microscope. Groups were compared by two-way ANOVA with Bonferroni post hoc test. Results: MU reduced fibroblast viability in a concentration-dependent manner, with an IC50 of 29.77 µg/mL compared with 58.21 µg/mL for the empty carrier and 78.80 µg/mL for pure madecassoside (the latter two extrapolated beyond the highest tested concentration). At 30 µg/mL, viability after MU treatment was significantly lower than after pure madecassoside (65.1% vs 104.4%; p < 0.05). MU was the only sample that reduced viability below 50% within the tested range. Conclusion: Loading madecassoside into the ultra-small unilamellar nanocarrier increased its cytotoxic potential against keloid fibroblasts, as reflected by an approximately 2.6-fold lower IC50 than that of pure madecassoside, with the carrier itself contributing partly to this effect.
Keywords: madecassoside; ultra-small unilamellar nanocarrier; keloid fibroblast; MTT assay; IC50; cytotoxicity
Keywords:
madecassoside, ultra-small unilamellar nanocarrier, keloid fibroblast, MTT assay, IC50, cytotoxicityDOI
https://doi.org/10.22270/jddt.v16i11.8092References
1. Sadick NS, Karcher C, Palmisano L. Cosmetic dermatology of the aging face. Clin Dermatol. 2009;27(3 Suppl):S3-12. https://doi.org/10.1016/j.clindermatol.2008.12.003
2. Alzate J, Villamil-guevara J, Adarme-malaver J, Gutiérrez-ochoa L, Piedrahita LA, Pinilla-obregon M. Efficacy of emerging therapies versus traditional therapies in the treatment of hypertrophic scars and keloids : A systematic review. 2025;11(5):1-16. https://doi:10.57662/am.v11i3.17027
3. Darougheh A, Asilian A, Shariati F. Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. Clin Exp Dermatology, 2007;4(34):219-223. https://doi.org/10.1111/j.1365-2230.2007.02631.x PMid:19018794
4. Betarbet U, Blalock TW. Keloids: a review of etiology, prevention, and treatment. J Clin Aesthet Dermatol. 2020;13(2):33-43.
5. Walsh LA, Wu E, Pontes D, Kwan KR, Poondru S, Miller CH. Keloid treatments: an evidence-based systematic review of recent advances. Syst Rev. 2023;12(1):42. https://doi.org/10.1186/s13643-023-02192-7 PMid:36918908 PMCid:PMC10012475
6. Chandra AF, Kamayana J, Tunjung N, Rini IS. Comparative efficacy and recurrence of combination therapies in keloid management: a systematic review and network meta-analysis. Plast Reconstr Surg Glob Open. 2025;13(8):e7048. https://doi.org/10.1097/GOX.0000000000007048 PMid:40771257 PMCid:PMC12327581
7. Zhang Y, Cheng C, Wang S, Xu M, Zhang D, Zeng W. Knockdown of FOXM1 inhibits activation of keloid fibroblasts and extracellular matrix production via inhibition of TGF-β1/Smad pathway. Life Sci. 2019;232:116637. https://doi.org/10.1016/j.lfs.2019.116637 PMid:31288014
8. Kobayashi T, Kim HJ, Liu X, Sugiura H, Kohyama T, Fang Q. Matrix metalloproteinase-9 activates TGF-β and stimulates fibroblast contraction of collagen gels. Am J Physiol Lung Cell Mol Physiol. 2014;306(11):L1006-15. https://doi.org/10.1152/ajplung.00015.2014 PMid:24705725
9. Pooprommin P, Manaspon C, Dwivedi A, Mazumder A, Sangkaew S, Wanmasae S. Alginate/pectin dressing with niosomal mangosteen extract for enhanced wound healing: evaluating skin irritation by structure-activity relationship. Heliyon. 2022;8(12):e12032. https://doi.org/10.1016/j.heliyon.2022.e12032 PMid:36506386 PMCid:PMC9727648
10. Bandopadhyay S, Mandal S, Ghorai M, Jha NK, Kumar M, Radha. Therapeutic properties and pharmacological activities of asiaticoside and madecassoside: a review. J Cell Mol Med. 2023;27(5):593-608. https://doi.org/10.1111/jcmm.17635 PMid:36756687 PMCid:PMC9983323
11. Bandopadhyay S, Mandal S, Ghorai M, et al. Therapeutic properties and pharmacological activities of asiaticoside and madecassoside : A review. 2023;(September 2022):593-608. https://doi.org/10.1111/jcmm.17635 PMid:36756687 PMCid:PMC9983323
12. Murakami T, Shigeki S. Pharmacotherapy for keloids and hypertrophic scars. Int J Mol Sci. 2024;25(9):4674. https://doi.org/10.3390/ijms25094674 PMid:38731893. PMCid:PMC11083137
13. Liu J, Li Y, Yang C, Zhao B. Unraveling the mechanisms of madecassoside derivatives in wound healing: network pharmacology and experimental validation. Pharmaceuticals. 2025;18(9):1292. https://doi.org/10.3390/ph18091292 PMid:41011163 PMCid:PMC12472257
14. Lu W, Luo D, Chen D, et al. Systematic Study of Paeonol/Madecassoside Co-Delivery Nanoemulsion Transdermal Delivery System for Enhancing Barrier Repair and Anti-Inflammatory Efficacy. Molecules. 2023;28(13). https://doi.org/10.3390/molecules28135275 PMid:37446936 PMCid:PMC10343821
15. Chairunisa U, Lucida H, Julianto T. Development and Characterization of Madecassoside-Loaded Ultra-Small Unilamellar Vesicles for Enhanced Transdermal Anti-Keloids. Int J Appl Pharm. 2026;18(5). https://doi.org/10.22159/ijap.2026v18i5.58939
16. Ochi MM, Amoabediny G, Rezayat SM, Akbarzadeh A, Ebrahimi B. In vitro co-delivery evaluation of novel pegylated nano-liposomal herbal drugs of silibinin and glycyrrhizic acid (nano-phytosome) to hepatocellular carcinoma cells. Cell J. 2016;18(2):135-148. http://doi:10.22074/cellj.2016.4308
17. Jacob S, Kather FS, Boddu SHS, Shah J, Nair AB. Innovations in nanoemulsion technology: enhancing drug delivery for oral, parenteral, and ophthalmic applications. Pharmaceutics. 2024;16(10):1333. https://doi.org/10.3390/pharmaceutics16101333 PMid:39458662 PMCid:PMC11510719
18. Babazadeh A, Zeinali M, Hamishehkar H. Nano-phytosome: a developing platform for herbal anti-cancer agents in cancer therapy. Curr Drug Targets. 2018;19(2):170-180. https://doi.org/10.2174/1389450118666170508095250 PMid:28482783
19. Nastiti CMRR, Ponto T, Mohammed Y, Roberts MS, Benson HAE. Novel nanocarriers for targeted topical skin delivery of the antioxidant resveratrol. Pharmaceutics. 2020;12(2):108. https://doi.org/10.3390/pharmaceutics12020108 PMid:32013204 PMCid:PMC7076350
20. Chodon T, Sugihara T. Keloid-Derived Fibroblasts Are Refractory to Fas- Mediated Apoptosis and Neutralization of Autocrine Transforming Growth Factor-  1 Can Abrogate this Resistance. Am J Pathol. 2000;157(5):1661-1669. https://doi.org/10.1016/S0002-9440(10)64803-1PMid:11073825 PMCid:PMC1885731
21. Kong Y xiang, Li Z shuai, Liu Y bo, et al. FOXO4-DRI induces keloid senescent fi broblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Commun Biol. Published online 2025. https://doi.org/10.1038/s42003-025-07738-0 PMid:39994346 PMCid:PMC11850796
Published
Abstract Display: 0
PDF Downloads: 0
PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Ully Chairunisa, Henny Lucida, Tommy Julianto, Hendriati

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

.